These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 17900650)

  • 1. Neutralizing antibodies decrease the envelope fluidity of HIV-1.
    Harada S; Monde K; Tanaka Y; Kimura T; Maeda Y; Yusa K
    Virology; 2008 Jan; 370(1):142-50. PubMed ID: 17900650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of membrane fluidity on human immunodeficiency virus type 1 entry.
    Harada S; Yusa K; Monde K; Akaike T; Maeda Y
    Biochem Biophys Res Commun; 2005 Apr; 329(2):480-6. PubMed ID: 15737612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
    Armstrong SJ; McInerney TL; McLain L; Wahren B; Hinkula J; Levi M; Dimmock NJ
    J Gen Virol; 1996 Dec; 77 ( Pt 12)():2931-41. PubMed ID: 9000083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.
    Allaway GP; Ryder AM; Beaudry GA; Maddon PJ
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):581-7. PubMed ID: 8369162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5.
    Ou W; Lu N; Yu SS; Silver J
    J Virol; 2006 Mar; 80(5):2539-47. PubMed ID: 16474160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of envelope molecules shown by different sensitivities to anti-V3 neutralizing antibody and CXCR4 antagonist regulates the formation of multiple-site binding of HIV-1.
    Harada S; Yusa K; Maeda Y
    Microbiol Immunol; 2004; 48(4):357-65. PubMed ID: 15107547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adsorption and infectivity of human immunodeficiency virus type 1 are modified by the fluidity of the plasma membrane for multiple-site binding.
    Harada S; Akaike T; Yusa K; Maeda Y
    Microbiol Immunol; 2004; 48(4):347-55. PubMed ID: 15107546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV vaccine design and the neutralizing antibody problem.
    Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
    Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
    [No Abstract]   [Full Text] [Related]  

  • 11. Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion-active intermediate state.
    Sadler K; Zhang Y; Xu J; Yu Q; Tam JP
    Biopolymers; 2008; 90(3):320-9. PubMed ID: 18338371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.
    Huskens D; Van Laethem K; Vermeire K; Balzarini J; Schols D
    Virology; 2007 Apr; 360(2):294-304. PubMed ID: 17123566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates.
    Haynes BF; Ma B; Montefiori DC; Wrin T; Petropoulos CJ; Sutherland LL; Scearce RM; Denton C; Xia SM; Korber BT; Liao HX
    Virology; 2006 Feb; 345(1):44-55. PubMed ID: 16242749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs.
    Koefoed K; Farnaes L; Wang M; Svejgaard A; Burton DR; Ditzel HJ
    J Immunol Methods; 2005 Feb; 297(1-2):187-201. PubMed ID: 15777942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247.
    Matsushita S; Takahama S; Shibata J; Kimura T; Shiozaki K; Eda Y; Koito A; Murakami T; Yoshimura K
    Hum Antibodies; 2005; 14(3-4):81-8. PubMed ID: 16720978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody.
    Lee HK; Scanlan CN; Huang CY; Chang AY; Calarese DA; Dwek RA; Rudd PM; Burton DR; Wilson IA; Wong CH
    Angew Chem Int Ed Engl; 2004 Feb; 43(8):1000-3. PubMed ID: 14966891
    [No Abstract]   [Full Text] [Related]  

  • 17. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41.
    Burrer R; Haessig-Einius S; Aubertin AM; Moog C
    Virology; 2005 Mar; 333(1):102-13. PubMed ID: 15708596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope.
    Zolla-Pazner S; Cohen SS; Krachmarov C; Wang S; Pinter A; Lu S
    Virology; 2008 Mar; 372(2):233-46. PubMed ID: 18061228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural studies of human HIV-1 V3 antibodies.
    Stanfield RL; Wilson IA
    Hum Antibodies; 2005; 14(3-4):73-80. PubMed ID: 16720977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.
    Mester B; Manor R; Mor A; Arshava B; Rosen O; Ding FX; Naider F; Anglister J
    Biochemistry; 2009 Aug; 48(33):7867-77. PubMed ID: 19552398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.